| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2499922 | Farmacéuticos de Atención Primaria | 2012 | 7 Pages |
Abstract
It shows a review of the new oral anticoagulants (dabigatran, rivaroxaban and apixaban). The paper evaluates the efficacy, safety and effectiveness of these drugs, including comparatively, and in relation to the classical K antagonists anticoagulants (warfarin and acenocumarol). Establishing the place of new oral anticoagulants in therapy based on patient characteristics and taking into account the risks and benefits associated with these new treatments, which have yet to be fully informed of its safety profile.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
M.C. Montero Balosa, R.M. Moya RodrÃguez,